文献速递甲状腺疾病

甲状腺功能与人类肝、心、肺纤维化风险:系统综述与荟萃分析

Thyroid Function and the Risk of Fibrosis of the Liver, Heart, and Lung in Humans: A Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2020-02-13

该系统综述与荟萃分析检索截至2019年6月14日的观察性研究,纳入18项研究,发现血清促甲状腺激素较高和甲状腺激素较低通常与纤维化可能性较高相关;与甲状腺功能正常相比,显性和亚临床甲状腺功能减退与肝、心、肺纤维化可能性较高相关;荟萃分析中显性和亚临床甲状腺功能减退与肝纤维化风险增加相关,汇总OR分别为2.81和2.12,证据主要基于横断面数据。

要点

  • 血清促甲状腺激素较高和甲状腺激素较低通常与肝、心、肺纤维化可能性较高相关。
  • 与甲状腺功能正常相比,显性和亚临床甲状腺功能减退与肝、心、肺纤维化可能性较高相关。
  • 荟萃分析中显性甲状腺功能减退与肝纤维化风险增加相关,汇总OR为2.81(95%CI 1.74-4.53)。

核心结论

  • 本研究提示低甲状腺功能与肝、心、肺慢性纤维化疾病可能性增加相关。
  • 证据主要基于横断面数据,需要前瞻性研究和随机临床试验来探究甲状腺激素及其类似物对纤维化发生和进展的潜在疗效。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Medline Ovid、Embase Ovid和Web-of-Science从建库至2019年6月14日发表的观察性研究。
  • 共纳入18项研究,其中11项报告肝纤维化、4项报告心肌纤维化、3项报告肺纤维化。
  • 研究人群样本量范围为36至7259名受试者,平均年龄中位数51岁(范围36-69),女性比例中位数53%(范围17-100)。
  • 研究质量采用纽卡斯尔-渥太华量表评价,偏倚风险为低至中至高。
  • 采用Mantel-Haenszel法合并探讨甲状腺功能减退与肝纤维化关联研究的比值比(OR)。

主要发现

  • 血清促甲状腺激素较高和甲状腺激素较低通常与纤维化可能性较高相关。
  • 与甲状腺功能正常相比,显性和亚临床甲状腺功能减退与肝纤维化可能性较高相关(7项研究中6项支持)。
  • 与甲状腺功能正常相比,显性和亚临床甲状腺功能减退与心脏纤维化可能性较高相关(3项研究中3项支持)。
  • 与甲状腺功能正常相比,显性和亚临床甲状腺功能减退与肺纤维化可能性较高相关(3项研究中3项支持)。
  • 荟萃分析中,显性甲状腺功能减退与肝纤维化风险增加相关(汇总OR 2.81,95%CI 1.74-4.53,异质性I²=31.4%),亚临床甲状腺功能减退与肝纤维化风险增加相关(汇总OR 2.12,95%CI 1.45-3.12,异质性I²=0%),未见发表偏倚证据。

关键数值与推荐

  • 显性甲状腺功能减退与肝纤维化关联的汇总OR为2.81(95%CI 1.74-4.53),异质性I²=31.4%。
  • 亚临床甲状腺功能减退与肝纤维化关联的汇总OR为2.12(95%CI 1.45-3.12),异质性I²=0%。
  • 研究人群平均年龄中位数51岁(范围36-69),女性比例中位数53%(范围17-100)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据主要基于横断面数据。
  • 需要前瞻性研究和随机临床试验来探究甲状腺激素及其类似物对纤维化发生和进展的潜在疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Fibrotic diseases have an unclear etiology and poor prognosis. Fluctuations in thyroid function may play a role in the development of fibrosis, but evidence is fragmented and inconclusive. This systematic review and meta-analysis aimed to investigate the association of thyroid function with fibrotic diseases of the liver, heart, and lung in humans. Methods: We searched PubMed, Medline Ovid, Embase Ovid, and Web-of-Science for studies published from inception to 14 June 2019, to identify observational studies that investigated the association of thyroid function with fibrosis of the liver, heart, and lung in humans. Study quality was evaluated by the Newcastle-Ottawa Scale. The Mantel-Haenszel method was used to pool the odds ratios (ORs) of studies investigating the association of hypothyroidism with liver fibrosis. Results: Of the 2196 identified articles, 18 studies were included in the systematic review, of which 11 studies reported on liver fibrosis, 4 on myocardial fibrosis, and 3 on pulmonary fibrosis. The population sample size ranged from 36 to 7259 subjects, with median mean age 51 years (range, 36-69) and median percentage of women 53 (range, 17-100). The risk of bias of studies was low to moderate to high. Higher serum thyrotropin and lower thyroid hormone levels were generally associated with higher likelihood of fibrosis. Compared with euthyroidism, overt and subclinical hypothyroidism was associated with a higher likelihood of fibrosis in the liver (six of seven studies), heart (three of three studies), and lung (three of three studies). Based on the results of the seven studies included in the meta-analysis, overt and subclinical hypothyroidism was associated with an increased risk of liver fibrosis (pooled OR, 2.81; 95% confidence interval [CI], 1.74-4.53; heterogeneity, I2 31.4%; pooled OR, 2.12; CI, 1.45-3.12; heterogeneity, I2 0%; respectively), without evidence of publication bias. Conclusions: This study suggests that low thyroid function is associated with increased likelihood of chronic fibrotic diseases of the liver, heart, and lung. However, the evidence is mainly based on cross-sectional data. Prospective studies and randomized clinical trials are needed to investigate the potential efficacy of thyroid hormone and its analogs on the occurrence and progression of fibrosis.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bano A, Chaker L, Muka T, et al. Thyroid Function and the Risk of Fibrosis of the Liver, Heart, and Lung in Humans: A Systematic Review and Meta-Analysis. Thyroid. 2020. PMID: 31910097. doi:10.1089/thy.2019.0572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。